JULY 23, 2021 | EYEWORLD DAILY NEWS | 13
References: 1. VEVYE
®
(cyclosporine ophthalmic solution) 0.1% [package insert]. Harrow IP, LLC; 2024. 2. Cequa
®
(cyclosporine ophthalmic solution) .09% [package
insert]. Sun Ophthalmics, LLC; 2024. 3. Restasis
®
(cyclosporine ophthalmic emulsion) 0.05% [package insert]. Allergan, LLC; 2024. 4. Data on file.
VEVYE and the VEVYE logo are trademarks of Novaliq GmbH. Trademarks referenced herein are held by their respective owners.
Harrow and the Harrow logo are registered trademarks of Harrow IP, LLC. © 2024 Harrow. All Rights Reserved. VYE-00107 02/24
* In pooled Phase 3 studies.
** An open-label, single-arm, extension study
INDICATION AND USAGE: VEVYE (cyclosporine ophthalmic
solution) 0.1% is indicated for the treatment of the signs and
symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
• Potential for Eye Injury and Contamination – To avoid the
potential for eye injury and/or contamination, patients should
not touch the bottle tip to the eye or other surfaces.
• Use with Contact Lenses – VEVYE should not be
administered while wearing contact lenses. If contact lenses
are worn, they should be removed prior to administration of the
solution. Lenses may be reinserted 15 minutes following the
administration of VEVYE.
Adverse Reactions
In clinical trials with 738 subjects receiving at least 1 dose of
VEVYE, the most common adverse reactions were instillation site
reactions (8%) and temporary decreases in visual
acuity (3%).
You are encouraged to report negative side effects of prescription
drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-
1088.
For additional information about VEVYE, please see Brief
Summary on adjacent page and Full Prescribing Information
at vevye.com.
VEVYE
®
(cyclosporine ophthalmic solution) 0.1% is the first and only water-
free cyclosporine dissolved in a semifluorinated alkane (perfluorobutylpentane)
approved to treat both the signs and symptoms of dry eye disease.
1-3
In clinical studies,
• 56.8% of patients achieved 3 or more grades of improvement in total
corneal fluorescein staining at Day 15
*4
• 66.4% of patients showed at least 3 grades of improvement in corneal
staining at Day 29
*4
• 99.8% of patients experienced no or mild instillation site pain**
4
• VEVYE provided sustained improvement over 12 months
4
A Different Cyclosporine
Now Available!
Scan or visit vevye.com
to learn more
